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FMS-like tyrosine kinase 3 (FLT3) is a key driver of acute myeloid leukemia (AML). Several tyrosine 
kinase inhibitors (TKIs) targeting FLT3 have been evaluated clinically, but their effects are limited when 
used in monotherapy due to the emergence of drug-resistance. Thus, a better understanding of drug-
resistance pathways could be a good strategy to explore and evaluate new combinational therapies 
for AML. Here, we used phosphoproteomics to identify differentially-phosphorylated proteins in 
patients with AML and TKI resistance. We then studied resistance mechanisms in vitro and evaluated 
the efficacy and safety of rational combinational therapy in vitro, ex vivo and in vivo in mice. Proteomic 
and immunohistochemical studies showed the sustained activation of ERK1/2 in bone marrow samples 
of patients with AML after developing resistance to FLT3 inhibitors, which was identified as a common 
resistance pathway. We examined the concomitant inhibition of MEK-ERK1/2 and FLT3 as a strategy to 
overcome drug-resistance, finding that the MEK inhibitor trametinib remained potent in TKI-resistant 
cells and exerted strong synergy when combined with the TKI midostaurin in cells with mutated and 
wild-type FLT3. Importantly, this combination was not toxic to CD34+ cells from healthy donors, but 
produced survival improvements in vivo when compared with single therapy groups. Thus, our data 
point to trametinib plus midostaurin as a potentially beneficial therapy in patients with AML.
Activating mutations in FMS-like tyrosine kinase 3 (FLT3) are present in up to 35% of patients with acute myeloid 
leukemia (AML). FLT3 is a member of the class III receptor tyrosine kinase family and plays important roles in 
modulating the proliferation and differentiation of hematopoietic stem/progenitor cells by activating downstream 
mitogenic signaling pathways such as Ras/MAPK, JAK/Stat5, and PI3K-Akt1,2. Two major classes of activating 
mutations have been identified in FLT3: internal tandem duplications (ITDs) of 3 to 400 bp within the juxtamem-
brane domain (JMD), which is the most prevalent form of mutant FLT33; and point mutations in the activation 
loop4 of the tyrosine kinase domain (TKD). Less common mutations include activating point mutations in a 
16-amino-acid stretch of the FLT3 JMD3,5,6 or ITDs in the TKD-17. All of these mutations ultimately drive consti-
tutive activation of the FLT3 receptor and activate its downstream oncogenic pathways5,7,8.
To date, more than 20 FLT3 inhibitors have been developed, and eight of them have been evaluated in clin-
ical trials9–11. For example, the tyrosine kinase inhibitor (TKI) sorafenib, which is currently approved for the 
treatment of renal cell carcinoma, hepatocellular carcinoma, and radioactive iodine-refractory thyroid cancer, 
produces a high response rate in FLT3-ITD-positive relapsed/refractory AML12. Moreover, a large phase III 
study demonstrated the efficacy of sorafenib in the upfront setting of young patients with AML, with superior 
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event-free survival, relapse-free survival, and leukemia-free survival in the sorafenib arm13. Another relevant TKI 
is midostaurin, which inhibits FLT3 and exhibits antiproliferative effects in mutant and wild-type (WT) FLT3 
cells14. The initial results of a phase III international study demonstrated a survival benefit in the midostaurin 
arm15. Indeed, midostaurin is the only FLT3 inhibitor approved in combination with intensive chemotherapy for 
adult patients with AML exhibiting activating FLT3 mutations10.
Despite these encouraging results, all of the TKIs tested so far have failed to show an efficient response in AML 
when used as a single drug8,9, and either did not generate a sufficient initial response, or failed to sustain therapeu-
tic benefits because of secondary resistance11. Among the possible mechanisms for these failures is the existence 
of independent, alternative survival pathways, such as casein kinase 2 alpha, CD47, CD123, PIM, PI3K/AKT/
mTORC, JAK/STAT, and MAPK1,3,16–20. Accordingly, the characterization of resistance mechanisms is important 
for the design of new drugs targeting downstream or parallel FLT3 pathways2,9.
Resistance to TKIs via ERK1/2 activation has been reported in different cancers, both in vitro and in vivo3,18. 
These observations suggest that ERK inhibition could overcome TKI resistance. Moreover, concomitant blockade 
of ERK1/2 and FLT3 signaling pathways may provide clinical benefit for the treatment of a subset of patients with 
AML, as previously suggested16,21,22.
In recent years, there has been great interest in developing clinically effective small-molecule inhibitors of 
MEK, the kinase upstream of ERK1/2, to inhibit the Ras-Raf-MEK-ERK1/2 pathway in cancer23. In the setting of 
AML, the MEK inhibitor trametinib has produced good results in preclinical models24, and it has been approved 
by the US Food and Drug Administration (FDA) for the treatment of several types of cancer. Trametinib was 
recently evaluated in a phase I/II study in patients with relapsed/refractory leukemia, showing activity in 
RAS-mutated AML25. Similarly, it has produced encouraging results in combination with TKIs in preclinical 
xenograft models of renal cell carcinoma26.
The present study provides evidence for the potential therapeutic benefit of the combination of the FLT3 
inhibitor midostaurin and the MEK inhibitor trametinib, not only in patients with mutated FLT3, but also in 
those without the mutation. The MEK inhibitor trametinib remained potent in TKI-resistant cells and exerted 
strong synergy when combined with midostaurin in mutated and wild-type FLT3 blast cells. Finally, the combina-
tion demonstrated statistically significant survival improvements in in vivo models when compared with vehicle 
and monotherapy groups.
Methods
Cell cultures, patients and healthy donors, and drugs. Human MOLM-13 (FLT3ITD/WT) and OCI-
AML3 (FLT3WT/WT) AML cell lines were obtained from the DSMZ culture collection (Braunschweig, Germany). 
MOLM-13 TKI-resistant cells (MOLM-13R) were produced from parental MOLM-13 after sustained and 
increasing exposure to sorafenib. For experiments of sorafenib-resistant cell enrichment (n = 3), 5,6-carboxyflu-
orescein diacetate succinimidyl ester (CFDA-SE)-stained MOLM-13 cells were treated with 5 µM sorafenib over 
48 hours, and then proliferative and viable cells (CFDA-SE+, Annexin V-) were sorted on the FACSAria™ Fusion 
sorter platform (BD Biosciences, San Jose, CA, USA).
For experiments on primary cells, mononuclear cells were obtained from patients with AML or healthy 
donors by standard density gradient centrifugation on Ficoll cushions. The main characteristics of the patients 
are summarized in Table 1. The study was approved by the Comité Ético de Investigación Clínica of the Instituto 
de Investigación Biomédica of the Hospital 12 de Octubre, and all patients and donors provided written informed 
consent in accordance with the Declaration of Helsinki.
Sorafenib and trametinib were purchased from Selleck Chemicals (Houston, TX, USA). Midostaurin was 
purchased from MedChemExpress (Sollentuna, Sweden). For details see Supplementary Information.
Whole exome sequencing. Exonic sequences from genomic DNA samples of patient #1 (bone marrow) 
at diagnosis were isolated, captured, amplified, and purified following the Ion TargetSeq™ Exome Enrichment 
manual (MAN0006730, Life Technologies S.A., Madrid, Spain). Sequencing was carried out on the Ion Proton™ 
System (ThermoFisher Scientific, Waltham, MA, USA). The Ion PGM system (ThermoFisher Scientific) was used 
for results validation. For details see Supplementary Information.
Liquid chromatography tandem-mass spectrometry analysis. Samples were lysed and digested 
following the standard filter-aided sample preparation method. Phosphopeptides were enriched in TiO2 
micro-columns and analyzed by liquid chromatography tandem-mass spectrometry (LC-MS/MS) using an LTQ 
Orbitrap Velos mass spectrometer (ThermoFisher Scientific). The MaxQuant and MaxLFQ platforms were used 
for analysis and quantification, respectively. Further data analysis was performed with Perseus. For details see 
Supplementary Information.
Histopathology and immunohistochemistry. Paraffin-embedded tissues from patients or mice were 
used for phospho-ERK1/2 (ref. 4370) or human CD4527(ref. 13917) detection, respectively (both from Cell 
Signaling Technology Inc., Danvers, MA, USA). Slides were counterstained with Carazzi’s hematoxylin solution 
(PanReac AppliChem, Darmstadt, Germany). For details see Supplementary Information.
Immunoblotting assays. Whole cell lysates from drug-treated cultured cells or AML patients’ mono-
nuclear cells were analyzed by western blotting (n = 3). Densitometry analysis of protein expression was cor-
rected for housekeeping protein expression and normalized to control samples. For details see Supplementary 
Information.
Drug sensitivity assay. Cell viability after monotherapy and combinational treatment was determined after 
48 or 72 hours of exposure to drugs or dimethyl sulfoxide (DMSO) in cell lines (n = 3–6) or primary cells (n = 5), 
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respectively, using the Cell Counting Kit-8 reagent from Sigma-Aldrich (St. Louis, MO, USA)28–30. For monother-
apy treatments, the half maximal inhibitory concentration (IC50) values were determined according to a nonlinear 
regression program (GraphPad Prism 5.01; GraphPad Software Inc., La Jolla, CA, USA). For combinational treat-
ments the combination index (CI) was calculated using Calcusyn software (Biosoft, Great Shelford, Cambridge, 
UK) or Compusyn software (ComboSyn Inc., Biosoft; Cambridge, UK), based on the Chou and Talalay method31. 
For details see Supplementary Information.
Colony-forming unit assays. To test treatment-related toxicity, CD34+ cells from healthy donors (n = 3) 
were exposed to the corresponding drugs or DMSO in methylcellulose medium (Methocult Express ref. 4437, 
StemCell Technologies SARL, Grenoble, France). Colony-forming units (CFU- granulocyte-monocyte and eryth-
roid colonies)32 were scored on day 13. For details see Supplementary Information.
In vivo studies. Female 5–6 week old NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice (The Jackson Laboratory, 
Bar Harbor, ME, USA) were injected with 5 × 106 OCI-AML3 (FLT3WT/WT) cells. Mice were treated daily with 
vehicle (10% DMSO, n = 7), trametinib (0.5 mg/kg, n = 7)24, midostaurin (50 mg/kg, n = 7)33 or the combination 
of both (n = 6) over 14 continuous days, and sacrificed when AML symptoms appeared along the experimental 
period of 57 days. Experiments involving animals were conducted at the Centro Nacional de Investigaciones 
Oncológicas (CNIO) in accordance with National and International Guidelines for Animal Care. The study pro-
tocol was approved by the Institutional Animal Care and Use Committee of the Comunidad de Madrid on April 
18th 2017. For details see Supplementary Information.
Statistical analysis. Data are presented as the mean and standard error of the mean (sem) or median values 
for survival analysis. Comparisons of means of variables between different groups were performed using the par-
ametric Student’s t test (two-sided) when the population followed a Gaussian distribution, or the non-parametric 
Mann-Whitney test when they did not. Overall survival curves were performed using the Kaplan-Meier estima-
tion, and the Mantel-Cox test was used for comparisons between groups. Univariable Cox proportional hazard 
ratio (HR) models were applied to investigate the influence of treatment in overall survival. A P ≤ 0.05 was con-
sidered significant. All statistical analyses were performed with GraphPad Prism software and SPSS v23 statistics 
software (North Castle, NY, USA).
Results
ERK1/2 pathway is activated in TKI-treated FLT3-mutated patients. Between 2008 and 2016, five 
patients with AML with mutated FLT3 received TKI treatment in our hospital and, after a few months, three of 
them developed resistance (patients #1, #2, and #3, see Table 1). Patient #1 was diagnosed with AML, French-
American-British (FAB) classification M1, presenting a point mutation in the JMD of FLT3 (L576P). Whole 
exome sequencing was used to confirm the absence of mutations in genes related to the main FLT3 downstream 
signaling pathways (ERK1/2, PI3K/AKT, and JAK/STAT). The patient was included in the PANOBINODARA 




















1 M 71 M1
Diagnosis BM 80
46, XY L576P No Sorafenib
A
d + 5 PBMC 67 (PB) B
d + 15 PBMC 40 (PB) C
d + 188 PBMC 81 (PB) C
d + 191 PBMC 81 (PB) B
d + 195 PBMC 81 (PB) B
2 M 63 M1
Diagnosis BM clot 93 47, XY; der 
(2;8), +5, −7, +8 L576Q No Sorafenib
D
Relapse BM clot 35 D
3 F 36 M2
Diagnosis BM clot 77
46, XX ITD NPM1, DNMT3A, CBL Midostaurin
D
Relapse BM clot 39 D
4 M 66 M1 Relapse BMMC 94 46, XY; +13,−21 WT biCEBPA No E
5 F 59 M5 Diagnosis BMMC 71 46, XX; del (8p) WT NPM1 No E
6 M 76 M1 Relapse BMMC 40 46, XY; −21 WT No No E
7 M 75 M1 Diagnosis BMMC 90 46, XY; del (8p) WT CEBPA No E
8 F 57 M5 Diagnosis BMMC 78 47,XX; + 8, inv (16) (p13q22) WT CBFB/ MYH11 No E
Table 1. AML patients’ main characteristics P (#), patient number; M, male; F, female; y, years; d + , day; 
PBMC, peripheral blood mononuclear cells; BM, bone marrow; BMMC, bone marrow mononuclear cells; PB, 
peripheral blood; ITD, internal tandem duplication; WT, wildtype; biCEBPA, biallelic CEBPA mutations; TKI, 
tyrosine kinase inhibitor; A, whole exome sequencing; B, western blot; C, liquid chromatography tandem-mass 
spectrometry analysis; D, immunohistochemistry analysis; E, drug sensitivity assay.
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clinical trial (NCT00840346), but relapsed after some months. Compassionate use of sorafenib was administered 
after informed consent and institutional review board approval. Despite a good initial response, the disease pro-
gressed and the patient died 33 months after AML diagnosis.
Two peripheral blood mononuclear cell (PBMC) samples from patient #1 (day +15 and +188 of sorafenib 
treatment) were analyzed by LC-MS/MS after phosphopeptide enrichment. We performed Kinase Set Enrichment 
Analysis of substrate motifs using MaxQuant software. The library was used to predict the putative kinase activi-
ties responsible for the input set of identified phosphosites. The analysis revealed seven enriched substrate motifs 
at the beginning of the treatment (day +15) and three enriched substrate motifs after sustained TKI treatment 
(day +188). ERK1/2 kinase substrate motif was the only motif identified at day 188 but not at day +15, indicating 
increased ERK1/2 activity after persistent TKI treatment (Fig. 1a).
We then analyzed phospho-ERK1/2 levels of three different PBMC samples from patient #1 (day +5, day 
+191, and day +195 of sorafenib treatment) by western blotting, finding that ERK phosphorylation levels were 
significantly higher after 6 months of sorafenib treatment (Fig. 1b).
To corroborate this potential mechanism of TKI resistance, we analyzed the levels of phospho-ERK1/2 levels 
in the other two TKI-treated patients. Patient #2 was also diagnosed with AML-M1, with a point mutation in 
the JMD of FLT3 (L576P). After several therapeutic lines, compassionate use of sorafenib was administered after 
informed consent and institutional review board approval, and the patient achieved a hematological response for 
5 months. Thereafter, bone marrow analysis revealed the recurrence of blasts, and the patient relapsed and died 
22 months after AML diagnosis. Patient #3 was diagnosed with AML-M2 with FLT3-ITD mutations and was 
recruited to a midostaurin clinical trial (NCT00651261). But despite having an initial good response, the patient 
relapsed 5 months later and died 8 months after AML diagnosis.
Paraffin-embedded bone marrow clots at diagnosis and relapse from patients #2 and #3 were analyzed by 
immunohistochemistry for phospho-ERK1/2 expression. The percentage of stained blasts was calculated 
before TKI treatment and at relapse. Significant differences were observed in both patients, with an increase 
in pERK1/2-positive blasts after TKI treatment. Higher levels of the phosphorylated form were recorded in 





GSEA of substrate moves at day +15 SIZE NES NOM p-val FDR q-val
PKC_KINASE_SUBSTRATE_MOTIF 236 2,27 0,0000 0,0247
CASEIN_KINASE_I_SUBSTRATE_MOTIF 268 2,18 0,0000 0,0193
GSK-3,_ERK1,_ERK2,_CDK5_SUBSTRATE_MOTIF 304 2,09 0,0011 0,0209
WW_DOMAIN_BINDING_MOTIF 304 2,08 0,0011 0,0171
PKA_KINASE_SUBSTRATE_MOTIF 239 2,02 0,0012 0,0235
CASEIN_KINASE_II_SUBSTRATE_MOTIF 155 1,99 0,0085 0,0259
B-ADRENERGIC_RECEPTOR_KINASE_SUBSTRATE_MOTIF 95 1,97 0,0053 0,0267
GSEA of substrate moves at day +188 SIZE NES NOM p-val FDR q-val
GSK-3,_ERK1,_ERK2,_CDK5_SUBSTRATE_MOTIF 275 2,35 0,0000 0,0146
WW_DOMAIN_BINDING_MOTIF 275 2,30 0,0012 0,0098
ERK1,2_KINASE_SUBSTRATE_MOTIF 246 2,04 0,0035 0,0303
pERK1/2 / ERK1/2


























































Figure 1. ERK1/2 is activated after continued TKI treatment in FLT3-mutated AML. (a) Venn diagram of 
enriched substrate motifs at the two points of treatment in patient #1. (b) Western blot of phospho-ERK1/2 
levels on different days (D) of treatment in patient #1. (c) Immunohistochemistry analysis of phospho-ERK1/2 
levels of patient #2 at diagnosis (above) and relapse after TKI treatment (below). (d) Immunohistochemistry 
analysis of phospho-ERK1/2 levels in patient #3 at diagnosis (above) and relapse after TKI treatment (below). 
*P ≤ 0.05. Scale bar: 5 µm.
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ERK1/2 pathway is activated after TKI resistance in vitro. Given these findings, we next tested 
whether ERK phosphorylation could be induced by the TKI treatment in vitro. To study resistance mechanisms, 
we used the MOLM-13 cell line that expresses FLT3-WT and FLT3-ITD. We observed that sustained treatment 
with increasing doses of sorafenib resulted in acquired resistance. This resistant cell line (MOLM-13R) was 
approximately 300-times less sensitive to sorafenib than the sensitive MOLM-13 cell line, which presented an IC50 
value in the picomolar range (IC50 values are shown in Fig. 2a). We next studied the effect of the TKI midostaurin 
and observed cross-resistance in the MOLM-13R cell line but effectiveness in sensitive MOLM-13 cells, with an 
IC50 value in the nanomolar range (see Supplementary Information, Supplementary Fig. S1).
Western blot analysis revealed that the MOLM-13R cell line showed significantly higher expression of 
pERK1/2 than parental MOLM-13 cells (Fig. 2b), similar to our observations in ex vivo patient cells (Fig. 1b). 
To validate ERK activation as a common mechanism of TKI resistance, we analyzed the resistant population 
selected after 48 h of sorafenib treatment in vitro using the same cell line background. Live treated proliferative 
cells (CFDA+ and Annexin V-), separated by sorting (see Supplementary Information, Supplementary Fig. S2), 
exhibited higher ERK1/2 phosphorylation levels than DMSO-treated control (Fig. 2c).
Trametinib is effective and has a synergistic effect with TKI in MOLM-13 and MOLM-13R cells. 
The apparent upregulation of the ERK1/2 pathway in TKI-resistant AML prompted us to hypothesize that 
patients with AML might benefit from ERK inhibition. We thus tested whether the MEK inhibitor trametinib 
is effective against both sensitive and TKI-resistant MOLM-13 cells. Both cell lines were equally sensitive to tra-
metinib, which efficiently inhibited cell growth in vitro in the low nanomolar range (IC50 MOLM-13 = 2.56 nM, 
IC50 MOLM-13R = 2.58 nM, Fig. 3a). These results indicate that there was no cross-resistance to trametinib in the 
tested cell lines, and suggest that trametinib may be beneficial in the context of TKI-resistant FLT3-mutated AML.
As trametinib in combination with TKIs might prevent the development of resistance, we next determined 
the effects of combining trametinib with sorafenib or midostaurin. Trametinib doses from 20 nM to 2.5 nM were 
tested with different doses of sorafenib (5 nM to 5 fM), and midostaurin (40 nM to 1.25 nM) to determine the CI. 
To be more restrictive, we only considered strong synergism when the CI was ≤0.5. After 48 h of simultaneous 
treatment, strong synergistic effects were observed for both combinations (Fig. 3b), indicating that the combina-
tion of trametinib with either of the tested TKIs potentiated the inhibition of MOLM-13 cell growth. The effects 
of combining trametinib (200 nM to 12.8 pM) with midostaurin (5 μM to 64 pM) were also evaluated in MOLM-
13R cells. Strong synergistic effects were observed in the TKI-resistant MOLM13-R cell culture (Supplementary 
Information, Supplementary Fig. S3a).
Figure 2. ERK1/2 pathway is activated after TKI-resistance in vitro. (a) Dose-response curve of sensitive 
or resistant (R) MOLM-13 cells. The IC50 value for sorafenib was almost 300 times higher than the control 
IC50 value in MOLM-13R cells. (b) pERK/ERK protein levels measured by western blotting in sensitive and 
resistant MOLM-13 cultures. The intensity of each band was normalized to the corresponding α-tubulin value. 
*P ≤ 0.05. (c) pERK/ERK levels of proliferative MOLM-13 cultures stained with CFDA-SE and sorted after 48 h 
of sorafenib treatment. pERK and ERK levels were analyzed by western blotting and normalized to α-tubulin. 
*P ≤ 0.05.
6Scientific RepoRtS |         (2019) 9:18630  | https://doi.org/10.1038/s41598-019-54901-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
Midostaurin + trametinib is the most effective combination of drugs in vitro. To explore the 
effects of the different drugs on FLT3 downstream signaling pathways, we tested drugs in vitro as monotherapy or 
in combination in MOLM-13 cells. Because a rebound phenomenon has been described after TKI treatment, with 
profound early inhibition followed by increasing ERK phosphorylation after incubation periods of 8–24 hours22 
we chose a shorter time window (3 hours).
Western blot analysis indicated a complete loss of pERK signaling after treatment with sorafenib, midostaurin, 
trametinib, and their combinations (Fig. 3c). Similarly, phospho-STAT5 levels were significantly decreased rel-
ative to the DMSO control after sorafenib or midostaurin treatment (Fig. 3c). By contrast, trametinib treatment 
led to a non-significant increase in pSTAT5 levels, but its combination with sorafenib or midostaurin reversed 
this trend. Analysis of AKT phosphorylation showed that whereas trametinib treatment had no effect on pAKT 
levels, its combination with the TKIs resulted in diminished pAKT levels, which was significant for the trametinib 
plus midostaurin combination. The same effects were observed after sustained TKI treatment, in TKI-resistant 
MOLM13-R cells (Supplementary Information, Supplementary Fig. S3b).
Finally, we also analyzed MAPK14 activation because of its role in the development of sorafenib resistance in 
other types of tumors18. Similar to the results for AKT phosphorylation, trametinib had no effect on pMAPK14 
levels, whereas sorafenib and midostaurin diminished them (Fig. 3c). Midostaurin plus trametinib was the only 
combination that notably decreased pMAPK14 levels. Thus, trametinib plus midostaurin seems to be the most 
effective combination, as it was capable of inhibiting the four analyzed pathways.
Midostaurin + trametinib exhibit synergy in vitro and ex vivo on FLT3 wild-type AML. Because 
midostaurin has activity against both mutated and wild-type FLT3, and the receptor is activated in almost all 
types of AML, its combination with trametinib might be a promising treatment for AML. We first tested whether 
ERK phosphorylation could also be induced by TKI treatment in vitro in the FLT3-WT cell line OCI-AML3. To 
do this, we treated OCI-AML3 cells with increasing doses of midostaurin. Western blot analysis revealed that 
this new resistant cell line showed higher expression of pERK1/2 than parental cells (Supplementary Information, 
Supplementary Fig. S4a).
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Figure 3. Trametinib effectively inhibits MOLM-13 and MOLM-13R cells and synergizes with sorafenib or 
midostaurin in MOLM-13 cells. (a) Dose-response curve of trametinib in sensitive and resistant (R) MOLM-
13 cells. (b) Normalized isobolograms for trametinib in combination with the TKIs sorafenib and midostaurin 
in MOLM-13 cells. (c) The levels of ERK1/2, STAT5, AKT, and MAPK14 and their phosphorylated forms 
were analyzed by western blotting in TKI-sensitive MOLM-13 cultures after monotherapy or combined drug 
treatments (200 nM of each treatment for 3 hours). Representative blots of three independent experiments, 
yielding equivalent results, are shown. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
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Both drugs were effective as monotherapy (Fig. 4a) and in combination (strong synergy, CI ≤ 0.5) (Fig. 4b) 
in the FLT3-WT cell line (OCI-AML3). Sorafenib was also effective as monotherapy (data not shown), but its 
combination with trametinib did not produce strong synergy (CI ≥ 0.5).
To study the possible role of MEK inhibition in the prevention of the emergence of acquired TKI resistance 
in FLT3-WT background, we examined the resistant population after 48 h of treatment of OCI-AML3 cells with 
midostaurin, trametinib or their combination. Live treated proliferative cells (CFDA+ and Annexin V-) showed 
decreased survival after the combination versus midostaurin alone (Supplementary Information, Supplementary 
Fig. S4b).
The enhanced antileukemic activity of trametinib plus midostaurin suggests that simultaneous inhibition 
of the ERK1/2 pathway and FLT3 signaling (wild-type or mutated) might be an effective treatment strategy for 
AML patients. We thus tested this combination ex vivo in cells from five patients (patient #4 to patient #8, all with 
FLT3-WT, see Table 1). Cytotoxicity and strong synergy (CI ≤ 0.5) were observed in each case; IC50 values for 
midostaurin were 0.28–0.87 µM, and for trametinib 3.86–29.73 nM (Fig. 4c), which are in line with the IC50 val-
ues obtained in vitro. Also, strong synergy effects (CI ≤ 0.5) were observed in the majority of tested combinations 
(Fig. 4d). Overall, these results support the use of midostaurin + trametinib in FLT3-WT AML cells.
Midostaurin + trametinib is safe ex vivo in healthy CD34+ cells. To test whether the combination 
of midostaurin plus trametinib could affect the colony formation of granulocyte-monocyte or erythroid colonies, 
we tested different combinational doses within the range of combination IC50 values observed for leukemic AML 
cells. Similar doses were able to inhibit leukemic cell growth without affecting healthy progenitor cells. Only mild 
cytotoxicity was observed at 0.25 µM midostaurin plus 0.05 µM trametinib (Fig. 5a), and slight toxicity, if any, was 
observed in the remainder of the assayed combinations. We would assume that the toxicity would be the same, or 
lower with each drug used separately.
Midostaurin + trametinib significantly improves survival over monotherapy in an in vivo AML 
model. Finally, to verify the efficacy and safety of the combination, we performed an in vivo study with 
OCI-AML3 cells injected into NSG mice. We found statistically significant survival differences between the 
midostaurin + trametinib combination (M + T) and the vehicle (V) group (P = 0.0134), the M + T and the T 
group (P = 0.0153), and the M + T and the M group (P = 0.0295), with the combination treatment significantly 
improving survival rates (Fig. 5b). Median survival in days was V (27), T (31), M (30) and M + T (45) and the 
OCI-AML3
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Figure 4. Midostaurin plus trametinib exert synergistic cytotoxicity in FLT3-WT AML samples in vitro 
and ex vivo. (a) Dose-response curve of trametinib and midostaurin in an FLT3-WT culture (OCI-AML3). 
(b) Normalized isobolograms for trametinib in combination with the TKI midostaurin in FLT3-WT OCI-
AML3 cells. (c) Dose-response curve of midostaurin and trametinib in five ex vivo FLT3-WT AML samples. 
(d) Normalized isobolograms for trametinib in combination with the TKI midostaurin in five ex vivo FLT3-
wildtype AML samples.
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percentage of death at the end of the experiment was 66.7% for M + T and 100% for the other groups (Fig. 5c). 
We then compared the risk of death from each treatment group versus combination group based on hazard ratio 
analysis: vehicle group [HR, 17.696; 95%CI, 2.965–105.613; P = 0.002], trametinib group [HR, 5.838; 95%CI, 
1.090–31.255; P = 0.039] and midostaurin group [HR, 5.617; 95%CI, 1.150–27.437; P = 0.033]. These results 
highlight the efficacy of the combination of trametinib plus midostaurin in vivo.
Histopathology examination of hematoxylin and eosin (H&E)- and human-CD45-stained bone mar-
row samples from mice showed proliferation of OCI-AML3 cells in vivo in all groups at necropsy (Fig. 5d). 
Remarkably, at the end of the experiment, two of the six mice in the combination treatment group did not show 
apparent leukemia symptoms, and one mouse had no infiltration of AML blasts in bone marrow, demonstrat-
ing that the combination controlled the progression of the disease for a longer period of time than the other 
groups. Histological examination of H&E-stained slides from spleen, liver and urinary bladder revealed some 
extramedullary tumors in vehicle, trametinib and midostaurin groups, but none were found in the combina-
tion treatment group (Fig. 5e). The percentage of mice bearing anatomically visible tumors is represented in 
Fig. 5e.
Taken together, the present data show that the combination of trametinib plus midostaurin can efficiently 
improve survival and control the progression of the disease for a longer period of time than monotherapy. These 
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Figure 5. Midostaurin plus trametinib is safe in healthy donor cells and significantly improves survival over 
monotherapy in vivo (a) Toxicity levels for both colony populations (granulocyte-monocyte or erythroid 
CFU) at indicated doses after 13 days of growth in methylcellulose medium. Data are expressed as percentage 
of toxicity relative to DMSO control (n = 3). (b) Survival curves of vehicle, trametinib, midostaurin and 
combination groups from in vivo studies. Statistically significant differences between combination group and 
vehicle (*P = 0.0134), combination and midostaurin group (*P = 0.0295), and combination and trametinib 
group (*P = 0.0153) were observed, with the combination treatment significantly improving survival. (c) 
Table showing median survival in days, % death at day 57 and hazard ratio and p-values from each group of 
treatment. (d) Representative hematoxylin and eosin (H&E) and human-CD45 stained sternum slides at 4X and 
40X showing OCI-AML3 cell infiltration in bone marrow. (e) H&E stained slides from spleen, liver and urinary 
bladder showing tumor or non-tumor sections in each case. The percentage of mice bearing anatomically visible 
tumors from each treatment group is represented below.
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Discussion
Distinct mutations in FLT3 lead to the constitutive activation of the receptor and its downstream path-
ways3–6,17,34–36. Several TKIs that achieve sustained in vivo inhibition of FLT3 have exhibited highly promising 
activity in early clinical studies10,34; however, none of them are able to ensure remission of AML as a single treat-
ment9, primarily because of secondary resistance. Among the possible mechanisms for these failures is the exist-
ence of independent alternative survival pathways, such as casein kinase 2 alpha, CD47, CD123, PIM, PI3K/AKT/
mTORC, JAK/STAT, and MAPK1,3,16–20. In the present study, we demonstrate that ERK activation is a common 
mechanism of TKI resistance in vitro and ex vivo. We detected ERK activation in an FLT3-mutated cell culture 
using two different means of resistance selection. Also, PBMCs from different patients harboring FLT3 mutations 
showed sustained ERK activation after the development of TKI resistance, as demonstrated by phosphoproteom-
ics, western blotting, and immunohistochemistry, with increased levels of pERK observed in the cytoplasm and 
nuclei of infiltrated blasts. pERK distribution is critical for substrate targeting in the nucleus (e.g., c-Fos and 
c-Myc) and the cytosol (e.g., ribosomal S6 kinases), although the mechanisms regulating this subcellular locali-
zation are unclear37. ERK activation has been previously suggested as a mechanism of TKI resistance, directly or 
indirectly, by the activation of upstream regulatory pathways3,17,22,38,39. Because of these results, we hypothesized 
that ERK inhibition, via its regulatory molecule MEK, might overcome TKI resistance, as suggested in other stud-
ies21,22,40. For example, Bruner et al.22, propose this combination after studying the incomplete response to TKI 
therapy in FLT3-ITD AML cells. According to these suggestions, we characterized the effect of the MEK inhibitor 
trametinib and its combination with the two TKIs sorafenib and midostaurin in vitro.
We demonstrate in vitro the potential use of trametinib in the context of FLT3-mutated AML, even in a back-
ground of TKI resistance. Indeed, previous studies have demonstrated the efficacy of trametinib in RAS-mutant 
AML24,25.
The activity of trametinib against TKI-resistant blasts suggests its possible use in combination with TKI to 
overcome resistance development. We therefore examined for synergism between trametinib and other TKIs, 
such as sorafenib, and midostaurin in order to look for the most beneficial combination. Of note, their combina-
tions presented strong synergy (CI ≤ 0.5). Our in vitro results suggest that sorafenib is the most potent compound, 
and its combination with trametinib showed strong synergy. Indeed, a recent clinical trial41 has evaluated the 
effect of trametinib plus sorafenib in patients with advanced hepatocellular cancer (NCT02292173), showing a 
good safety profile. Although sorafenib has shown encouraging results in AML clinical trials42,43, and it has been 
recommended for compassionate use in FLT3-mutated patients, it has not yet been approved. Whereas the addi-
tion of sorafenib to standard treatment in AML has not improved overall survival, the addition of midostaurin 
has resulted in a significant overall survival benefit44 and better tolerance than sorafenib45. In 2017, midostaurin 
plus chemotherapy was approved by the FDA for use in AML. In line with these results, we also observed a strong 
potency of midostaurin in FLT3-mutated cell lines and strong synergy when midostaurin was combined with 
trametinib in sensitive and TKI-resistant cultures. Interestingly, this combination was the only one able to inhibit 
the downstream FLT3 pathways described as potential mechanisms of resistance1,3,16,17,19,20.
As FLT3-WT and FLT3 mutants46 are sensitive to midostaurin, and the receptor is activated in almost all types 
of AML4,9,47,48, we would propose the extended use of its combination with trametinib, even in FLT3-WT patients. 
In this context, we demonstrate for the first time that ERK was also activated after sustained TKI treatment. 
Our results show that both compounds in monotherapy remain active against FLT3-WT in vitro and ex vivo. 
Interestingly, the IC50 obtained in vitro correlated with the ex vivo results. The combination was also synergistic 
in vitro and ex vivo, and showed no associated toxicity in CD34+ cells from healthy donors. Compellingly, the 
combination resulted in statistically significant improvements in vivo compared with control and single therapy 
groups. While the present study shows that trametinib is beneficial in the context of TKI resistance and the 
prevention of the emergence of resistance even in the FLT3-WT background, further studies will be needed 
to explore other potential pathways involved in dual resistance, which will hopefully facilitate new prevention 
strategies.
The ERK1/2 pathway is a relevant resistance mechanism in patients with AML treated with TKIs. Our data 
provide clear evidence of the potential therapeutic benefit of the combination of the FLT3 inhibitor midostaurin 
and the MEK inhibitor trametinib, not only in FLT3-mutated patients as previously suggested22, but also in those 
without the mutation, which increases the range of patients that could obtain benefits from the drug combination. 
This combination is synergistic in vitro, ex vivo, and in vivo. Lastly, the combination improves the survival rate in 
vivo. Overall, these data support a clinical trial of midostaurin plus trametinib in AML.
conclusions
ERK1/2 activation can promote TKI resistance in AML. We demonstrate that inhibition of the ERK1/2 pathway 
with trametinib, along with the use of a TKI, such as midostaurin, could be a beneficial therapeutic strategy in 
patients with AML and mutated or non-mutated FLT3.
Ethics approval and consent to participate. Studies involving human data and tissues were approved 
by our Institutional Review Board and all patients provided written informed consent in accordance with the 
Declaration of Helsinki.
Studies involving animals were conducted in accordance with National and International Guidelines for 
Animal Care and the study protocol was approved by the Institutional Animal Care and Use Committee of the 
Comunidad de Madrid on April 18th 2017.
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